Business Standard

Healthcare index nears all-time high, Sun Pharma zooms

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in EBITDA

Related News

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

The Healthcare index — which tracks the movement of pharma shares on the BSE —the largest gainer among the sectoral indices is up 70 points or 1% at 6,845, trading nears to its lifetime high of 6,871 touched on January 2011.

The index has outperforming by gaining 16.6% year-to-date, compared with 12.5% rise in the benchmark index Sensex.

Sun Pharma Industries is trading higher by 2% at Rs 607, extending its yesterday’s over 2% gain after a favourable verdict from the US Supreme Court in its patent case against Novo Nordisk.

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in earnings before interest, taxes, depreciation, and amortization (EBITDA) led by strong performance by Sun Pharma on the back of improvement in the profitability of Taro, and Cadila led by acquisitions, Glenmark Pharma and Torrent Pharma on a low base.

The research firm expects the sector will post a topline growth of 13.5% on year-on-year basis (excluding one-offs) and adjusted profit after tax (PAT) is expected to grow by 12.5% on YoY.

Read more on:   
|
|
|
|
|

Read More

Credit ratings fell the most in three years: CRISIL

According to CRISIL, the Indian arm of Standard & Poor which rates over 9,000 issuers in India, credit ratings have fallen the most in three ...

Quick Links

 

Market News

Thailand, Indonesia, Malaysia plan rubber exchange

The exchange will be operational in 18 months

Adani's controversial foray down under

SBI, however, says the loan will be disbursed only after proper due diligence

Fund managers to wait tilll next Budget for tax clarity

The proposal to treat their business income as capital gains was part of capital market reforms in this budget but I-T Dept will take longer

Less than 25% of shareholders participate in delistings: Experts

They say 25% rule could prove major hurdle for exiting companies

Equity MFs turn net sellers; shares worth Rs 675 crore sold

Investment managers say it's nothing but a tactical sell call

Back to Top